Answers are grounded in this paper and cite their sources.
Background Due to the rapidly increasing availability of metabolomics data in prospective studies, an update of the meta evidence on metabolomics and type 2 diabetes risk is warranted. Purpose To conduct an updated systematic review and meta-analysis of plasma, serum, or urine metabolite markers and incident type 2 diabetes. Data Sources PubMed and Embase. Study Selection Prospective observational studies investigating the relationship between plasma, serum, or urine metabolites using high throughput techniques and incident type 2 diabetes. Data Extraction Baseline metabolites per-standard deviation risk estimates and 95% confidence intervals for incident type 2 diabetes were extracted from all eligible studies. Data Synthesis Sixty-one reports with 71,196 participants and 11,771 type 2 diabetes cases/events were included in the updated review. Overall, 412 metabolites were meta-analyzed, of which 123 were statistically significantly associated (FDR-P<0.05) with type 2 diabetes risk. Higher plasma and serum levels of certain amino acids (branched-chain, aromatic, alanine, glutamate, lysine, and methionine), carbohydrates and energy-related metabolites (mannose, trehalose, pyruvate), acylcarnitines (C4DC, C4OH, C5, C5OH, C8:1), the majority of meta-analyzed glycerolipids (di- and triacylglycerols), (lyso)phosphatidylethanolamines, and ceramides were associated with higher risk of type 2 diabetes (hazard ratio [HR] 1.07-2.58). Higher levels of glycine, glutamine, betaine, indolepropionate, and (lyso)phosphatidylcholines were associated with lower type 2 diabetes risk (HR 0.69-0.90). Limitations Substantial heterogeneity (I2>50%, t2>0.1) was observed for some of the metabolites. Conclusions Several plasma and serum metabolites, including amino acids, lipids, and carbohydrates are associated with type 2 diabetes risk.
No takes yet. Share an insight, caveat, or question.
Morze et al. (2022) studied this question.